IASLC World Conference on Lung Cancer
Marina C. Garassino, MD, on COVID-19 and Thoracic Malignancies: TERAVOLT Registry
Marina C. Garassino, MD, of the Istituto Nazionale dei Tumori di Milano, discusses the global registry she and her colleagues created to track and address the 35% higher mortality risk from COVID-19 a...
Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease
Leora Horn, MD, of Vanderbilt University, discusses phase III results from the eXalt3 trial, which suggest that ensartinib, a novel, next-generation ALK inhibitor, is superior to crizotinib in terms o...
Misako Nagasaka, MD, on NSCLC: Sintilimab, Pemetrexed, and Platinum as First-Line Therapy
Misako Nagasaka, MD, of the Barbara Ann Karmanos Cancer Institute, discusses results of the ORIENT-11 trial, which showed that, although sintilimab plus pemetrexed and platinum significantly improved ...
Paul Baas, MD, PhD, on Mesothelioma: First-Line Nivolumab Plus Ipilimumab vs Chemotherapy
Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses results of the CheckMate 743 trial, which suggests nivolumab plus ipilimumab should be considered the new standard of care in first-l...
